Assessing How Normal Variations in CT Scanning Affects Its Interpretation
Stability of Radiomic Features for Abdominal Tumors on Contrast Enhanced CT
1 other identifier
observational
169
1 country
2
Brief Summary
The purpose of the study is to see how measurements of tumor differences vary with slight changes in CT scan parameters. Reproducible radiomic features can be extracted for abdominal tumors, and specifically colorectal liver metastases, imaged with clinical CT scanners even in the setting of variable scan parameters and variable contrast timing. Participants will be consented to undergo an additional CT of their abdomen.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jan 2017
Longer than P75 for all trials
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 27, 2017
CompletedFirst Submitted
Initial submission to the registry
January 30, 2017
CompletedFirst Posted
Study publicly available on registry
January 31, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 27, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
January 27, 2027
April 22, 2026
April 1, 2026
10 years
January 30, 2017
April 17, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
assess the stability (reproducibility) of radiomic measurements obtained from repeat abdominal CT scans
There will be 18 cohorts, each cohort differing by the length of the time gap in acquisition and noise index. In addition each acquisition will be reconstructed in 21 different ways (combinations of 3 slice thicknesses and 7 ASiR levels).
2 years
Study Arms (18)
Cohort 1
-15 second time gap between routine abdominal CT and add on CT, Noise Index of 12
Cohort 2
-15 second time gap between routine abdominal CT and add on CT, Noise Index of 14
Cohort 3
-15 second time gap between routine abdominal CT and add on CT, Noise Index of 16
Cohort 4
-10 second time gap between routine abdominal CT and add on CT, Noise index 12
Cohort 5
-10 second time gap between routine abdominal CT and add on CT, Noise index 14
Cohort 6
-10 second time gap between routine abdominal CT and add on CT, Noise index 16
Cohort 7
\- 5 second time gap between routine abdominal CT and add on CT, Noise index 12
Cohort 8
\- 5 second time gap between routine abdominal CT and add on CT, Noise index 14
Cohort 9
\- 5 second time gap between routine abdominal CT and add on CT, Noise index 16
Cohort 10
\+ 5 second time gap between routine abdominal CT and add on CT, Noise index 12
Cohort 11
\+ 5 second time gap between routine abdominal CT and add on CT, Noise index 14
Cohort 12
\+ 5 second time gap between routine abdominal CT and add on CT, Noise index 16
Cohort 13
\+ 10 second time gap between routine abdominal CT and add on CT, Noise index 12
Cohort 14
\+ 10 second time gap between routine abdominal CT and add on CT, Noise index 14
Cohort 15
\+ 10 second time gap between routine abdominal CT and add on CT, Noise index 16
Cohort 16
\+ 15 second time gap between routine abdominal CT and add on CT, Noise 12
Cohort 17
\+ 15 second time gap between routine abdominal CT and add on CT, Noise 14
Cohort 18
\+ 15 second time gap between routine abdominal CT and add on CT, Noise 16
Interventions
Patients with colorectal liver metastases scheduled for abdominopelvic CECT will be consented to undergo an additional CT of their abdomen (termed add-on CT) within 15 seconds, before or after, their clinical portal venous phase CT (PV CT), which is performed at a fixed delay of 80 seconds at our institution.
Eligibility Criteria
Patients who undergo contrast enhanced CT scanning for colorectal liver metastases will be consented for one additional CT abdomen phase during the same imaging session.
You may qualify if:
- Patients ≥ 18 years of age on the day of signed informed consent
- Patients scheduled and approved for contrast enhanced CT that includes imaging of the abdomen and pelvis following the Department of Radiology standard of care protocol as per local institutional guidelines
- Patients with measurable colorectal liver metastases on prior imaging, with at least one tumor greater than 2.0 cm in axial maximal diameter
You may not qualify if:
- Patient who is pregnant and/or lactating
- Patient scheduled for CT that includes the abdomen with a multiphasic contrast enhanced protocol (e.g. Triple Phase or Quadruple Phase Liver CT)
- Patient who require reduced intravenous contrast dose based on the Department of Radiology contrast policy as per local institutional guidelines
- Any other medical condition, including mental illness or substance abuse, deemed by the Investigator to be likely to interfere with a patient's ability to sign informed consent, cooperate and participate in the study, or follow up procedures
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Memorial Sloan Kettering Cancer Centerlead
- Queen's Universitycollaborator
Study Sites (2)
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
MD Anderson Cancer Center, Texas (Data collection only)
Houston, Texas, 77030, United States
Related Links
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Kinh Gian Richard Do, MD, PhD
Memorial Sloan Kettering Cancer Center
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 30, 2017
First Posted
January 31, 2017
Study Start
January 27, 2017
Primary Completion (Estimated)
January 27, 2027
Study Completion (Estimated)
January 27, 2027
Last Updated
April 22, 2026
Record last verified: 2026-04